Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 20/20 | 0.86 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12998438 | 0.93 | PTK2 (0.85) | PTK2PTK2B | |
| SCHEMBL29853299 | 0.92 | PTK2 (1.00) | PTK2PTK2B | |
| SCHEMBL1628033 | 0.92 | PTK2 (1.00) | PTK2PTK2B | |
| SCHEMBL1628458 | 0.92 | PTK2 (1.00) | PTK2 | |
| SCHEMBL1626068 | 0.90 | PTK2 (1.00) | PTK2PTK2B | |
| SCHEMBL29853469 | 0.90 | PTK2 (1.00) | PTK2PTK2B | |
| SCHEMBL29853547 | 0.90 | PTK2 (1.00) | PTK2PTK2B | |
| SCHEMBL1628553 | 0.90 | PTK2 (1.00) | PTK2PTK2B | |
| SCHEMBL13806501 | 0.90 | PTK2 (0.81) | PTK2PTK2B | |
| SCHEMBL1627916 | 0.89 | PTK2 (0.88) | PTK2PTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2022-08-11 | — | — | US | disclosed |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2019-02-14 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2011-07-07 | — | — | US | disclosed |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2011-07-07 | — | — | US | disclosed |
| US-7928109-B2 | focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928109-B2 | focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928109-B2 | focal adhesion kinase inhibitor, i.e. FAK inhibitor; tyrosine kinase inhibitors; cancer, osteoporosis; e.g. N-methyl-4-({4-[({3-[methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100305099-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305099-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885 |
| US-10450297-B2 | Sulfonyl amide derivatives for the treatment of abnormal cell growth | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885 |
| US-20110166120-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885 |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885 |
| US-20190047979-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885 |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885 |
| US-20090054395-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885 |
| US-20100305099-A1 | DIAMINOPYRIDINES FOR THE TREATMENT OF DISEASES WHICH ARE CHARACTERISED BY EXCESSIVE OR ANOMAL CELL PROLIFERATION | BOD1L1, DPYD, MKI67 | PTK2 2418/4885PTK2B 1605/4885 |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | PTK2 4052/4885PTK2B 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.